In a significant ruling for pharmaceutical regulation in India, the Delhi High Court has reinstated the Indian government's ...

A diabetes drug may soon double as a treatment for liver disease. Dapagliflozin, an SGLT-2 inhibitor typically used for type 2 diabetes, significantly improved liver inflammation and scarring in ...

Jeff Somers is a freelancer who has been writing about writing, books, personal finance, and home maintenance since 2012. When not writing, Jeff spends his free time fixing up his old house. He has ...

In the phase 2 MIRO-CKD trial, 12 weeks of balcinrenone combined with dapagliflozin reduced albuminuria compared with dapagliflozin alone added to standard of care in patients with stage 3-4 CKD.

NEW ORLEANS, LA—Sodium-glucose cotransporter 2 (SGLT2) inhibition does not seem to be a solution to the problem of arrhythmia recurrence after catheter ablation for atrial fibrillation (AF), results ...

HOUSTON -- Adding an investigational nonsteroidal mineralocorticoid receptor antagonist (MRA) to an SGLT2 inhibitor led to a superior reduction in albuminuria among chronic kidney disease patients at ...

Sodium-glucose co-transporter 2 (SGLT2) inhibitors reduce albuminuria (excess albumin in the urine) and the risk of chronic kidney disease (CKD) progression, and certain mineralocorticoid receptor ...

AstraZeneca ((AZN)) announced an update on their ongoing clinical study. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to ...

Below, an edit of the best options well regarded by three board-certified dermatologists who reveal their favorite moisturizers for combination skin, from gel-creams to lightweight lotions. Each one ...

Cancer treatment has made remarkable strides. New drugs and technologies have changed outcomes for many patients, turning some once-fatal diagnoses into manageable conditions. Yet despite these ...

In patients with heart failure with mildly reduced or preserved ejection fraction (HFmrEF/HFpEF), adding the mineralocorticoid receptor antagonist (MRA) spironolactone to the SGLT2 inhibitor, ...

A clinical trial involving adolescents with type 1 diabetes (T1D) has found a combination therapy may reduce chronic kidney disease and improve health outcomes. The findings could help guide more ...